A critical review our current understanding of camptothecins, their shortcomings, and of the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance.…mehr
A critical review our current understanding of camptothecins, their shortcomings, and of the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance.Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Biochemistry, Pharmacology, and Chemistry.- Mechanism of Action of Topoisomerase 1 Poisons.- Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage.- Inhibitors of Topoisomerase I Function.- Cytotoxic Mechanisms of Topoisomerase 1 Inhibitors.- Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage.- Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs.- Mechanisms of Resistance to Camptothecins.- Recent Advances in Camptothecin Drug Design and Delivery Strategies.- Clinical Perspectives.- Clinical Experience With 9-Aminocamptothecin.- Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin).- Irinotecan.- Clinical Experience With Topotecan.- The Clinical Development of Lurtotecan.- Preclinical and Clinical Development of Exatecan (DX-951f).- Camptothecins in the Treatment of Primary Brain Tumors.- Camptothecins in the Treatment of Lung Cancer.- Use of Camptothecins in the Treatment of Leukemia and Related Disorders.
Biochemistry, Pharmacology, and Chemistry.- Mechanism of Action of Topoisomerase 1 Poisons.- Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage.- Inhibitors of Topoisomerase I Function.- Cytotoxic Mechanisms of Topoisomerase 1 Inhibitors.- Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage.- Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs.- Mechanisms of Resistance to Camptothecins.- Recent Advances in Camptothecin Drug Design and Delivery Strategies.- Clinical Perspectives.- Clinical Experience With 9-Aminocamptothecin.- Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin).- Irinotecan.- Clinical Experience With Topotecan.- The Clinical Development of Lurtotecan.- Preclinical and Clinical Development of Exatecan (DX-951f).- Camptothecins in the Treatment of Primary Brain Tumors.- Camptothecins in the Treatment of Lung Cancer.- Use of Camptothecins in the Treatment of Leukemia and Related Disorders.
Biochemistry, Pharmacology, and Chemistry.- Mechanism of Action of Topoisomerase 1 Poisons.- Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage.- Inhibitors of Topoisomerase I Function.- Cytotoxic Mechanisms of Topoisomerase 1 Inhibitors.- Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage.- Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs.- Mechanisms of Resistance to Camptothecins.- Recent Advances in Camptothecin Drug Design and Delivery Strategies.- Clinical Perspectives.- Clinical Experience With 9-Aminocamptothecin.- Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin).- Irinotecan.- Clinical Experience With Topotecan.- The Clinical Development of Lurtotecan.- Preclinical and Clinical Development of Exatecan (DX-951f).- Camptothecins in the Treatment of Primary Brain Tumors.- Camptothecins in the Treatment of Lung Cancer.- Use of Camptothecins in the Treatment of Leukemia and Related Disorders.
Biochemistry, Pharmacology, and Chemistry.- Mechanism of Action of Topoisomerase 1 Poisons.- Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage.- Inhibitors of Topoisomerase I Function.- Cytotoxic Mechanisms of Topoisomerase 1 Inhibitors.- Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage.- Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs.- Mechanisms of Resistance to Camptothecins.- Recent Advances in Camptothecin Drug Design and Delivery Strategies.- Clinical Perspectives.- Clinical Experience With 9-Aminocamptothecin.- Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin).- Irinotecan.- Clinical Experience With Topotecan.- The Clinical Development of Lurtotecan.- Preclinical and Clinical Development of Exatecan (DX-951f).- Camptothecins in the Treatment of Primary Brain Tumors.- Camptothecins in the Treatment of Lung Cancer.- Use of Camptothecins in the Treatment of Leukemia and Related Disorders.
Rezensionen
"...an excellent all-around reference appropriate for researchers or clinicians in anticancer drug literature." - Doody's Health Science Book Review Journal
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
